How does Health Canada decide if a new drug can be offered to Canadians?Speaker:
Stephanie Hardy
Stephanie joined Health Canada in 2003 where she is currently a manager in the Office of Policy and International Collaboration within the Biologics and Genetic Therapies Directorate. Her unit is responsible for the development of policies and guidance documents to support the regulatory review of biologic drug submissions.
Stephanie has a Master of Public Health degree from the University of Waterloo, a BSc. in Biomedical Toxicology from the University of Guelph, and is a graduate of Seneca College’s Pharmaceutical Regulatory Affairs and Quality Operations Post-Graduate Program. |
What kind of cost-benefit analysis determines if drugs will be paid by the province or a private Group Insurance Plan?Speaker:
Brent Fraser
Brent is CADTH Vice-President, Pharmaceutical Reviews, with responsibility for the CADTH Common Drug Review, the pan-Canadian Oncology Drug Review, therapeutic class reviews, and optimal use projects, as well as drug-related Environmental Scans, Horizon Scans, and Rapid Response. Brent and his team deliver high-quality, relevant, and timely assessments of drugs using the best available science, tools, and methodologies.
Brent is known as a thoughtful, listening, and collaborative leader who translates evidence into recommendations and actions. He combines a pharmacist’s appreciation for the clinical and human implications of his work with strategic skills developed over many years working in the field of drug funding decisions.
Brent holds an MBA from York University and a BSc. in Pharmacy from the University of Toronto. He is a member of the Ontario College of Pharmacists. |
Speaker:
Christine Than
Christine joined Aon Hewitt in September 2013 where she is a Senior Drug Solutions Consultant with the Health and Benefits team and is based out the Montreal office.
Christine is responsible for developing strategies at a national level in respect to drug claims management as well as drug utilization reviews. Moreover, she is responsible for drug trends monitoring and for modifications at legislative level which could affect drug plans.
Christine has held various positions in the health industry, and more specifically in health technologies. Furthermore, she has been Account Manager and Clinical Pharmacist within a major health solutions supplier. She also has extensive experience in advisory services for businesses as well as internal clients in her role as prescription drug expert. She also has several years of experience as a keynote speaker at industry conferences.
Christine hold a Bachelor’s Degree in Pharmacy from Université de Montréal and a Graduate Certificate in Health Care from McGill University. |